The FDA has delayed a decision on the approval of AstraZeneca’s camizestrant, deferring its ruling to review analyses filed ...

May 27 (Reuters) - AstraZeneca said on Wednesday the U.S. Food and Drug Administration has extended the decision deadline for ...

AstraZeneca and Daiichi Sankyo have secured approval from the US Food and Drug Administration (FDA) for Datroway (datopotamab ...

AstraZeneca (AZN) announced on Wednesday that the U.S. Food and Drug Administration has delayed a review of its marketing ...

The review extension comes weeks after an advisory panel found the evidence supporting the drug, camizestrant, inconclusive ...

(Reuters) -AstraZeneca has proposed price cuts to its drugs in the United States, its CEO said on Tuesday, days after unveiling a $50 billion investment to expand there, as President Donald Trump ...

An analyst said the decline in the stock was largely due to profit booking and did not indicate a reversal in the broader ...

AstraZeneca said the U.S. Food and Drug Administration is pushing back its decision on whether to approve a new breast-cancer drug in order to review additional data provided by the company. The U.K.

May 2026 US FDA decision date extended for SERENA-6 filing of camizestrant to enable review of additional data The US Food and Drug Administration (FDA) has informed AstraZeneca that it will extend ...

The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term ...

(Reuters) -AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat a type of lung cancer, marking the first approval of the therapy ...